Loxo Oncology (LOXO) Releases LOXO-101 Data; Oppenheimer Raises Price Target to $30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St set for higher open after Micron revives AI optimism, upbeat economic data
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Unusual 11 Mid-Day Movers 11/9: (XOMA) (PCL) (STRL) Higher; (RCAP) (FSTR) (EVEP) Lower
November 9, 2015 12:55 PM ESTRCS Capital (NYSE: RCAP) 47.0% LOWER; provided the following update as the Company continues to execute on its plan to rationalize its capital structure, increase financial flexibility and position the Company for long-term growth. As previously noted, the Company's Board of Directors has engaged Lazard Freres & Co. LLC to assist in the exploration of options to raise significant capital and to rationalize the Company's capital structure. As part of this process, the independent directors on the Board, led by Non-Executive Chairman Mark Auerbach, will negotiate and approve any proposals derived... More
Loxo Oncology (LOXO) Issues Encouraging Update on LOXO-101 Phase 1
November 9, 2015 6:17 AM ESTLoxo Oncology (NASDAQ: LOXO) announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Providing a LOXO-101 Phase 1 update, study investigators reported that, as of the October 20, 2015 data cutoff date, 30 patients with solid tumors refractory to standard therapy had been enrolled and treated, including six patients with cancers harboring TRK fusions.... More
